

## An Alternative Total Synthesis of Rutaecarpine and Vasicolinone Alkaloids<sup>1</sup>

József Kökösi<sup>a</sup>, György Szász<sup>a</sup> and István Hermecz<sup>b\*</sup>

<sup>a</sup> Institute for Pharmaceutical Chemistry, Semmelweis University  
of Medicine

<sup>b</sup> Chinoim Pharmaceutical and Chemical Works Ltd. P.O.Box 110.  
H-1325 Budapest, Hungary

**Abstract:** Rutaecarpine (**6**) and vasicolinone (**9**) alkaloids were alternatively prepared by Fischer indolization of 3-(phenylhydrazone)methyl)pyrroloquinazolinone (**4**) under thermal and acidic conditions, respectively.

Recently we reported<sup>2</sup> a facile total synthesis of rutaecarpine<sup>3</sup> (**6**) alkaloid of *Evodia Rutaecarpa*, by the Fischer indolization of 6-phenylhydrazone-6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-one prepared from 6,7,8,9-tetrahydro-11*H*-pyrido[2,1-*b*]quinazolin-11-one alkaloid<sup>4</sup>. Earlier rutaecarpine syntheses<sup>5</sup> built up the connection between C and E or B and D rings of the pentacyclic skeleton.

Vasicolinone (**9**) was isolated<sup>6</sup> from *Adhatoda vasica*, and Kaneko et al. prepared<sup>6c</sup> it by the acid catalyzed cyclization of 2-chloro-3-[(3-indol)-ethyl]quinazolin-4-one and the subsequent dimethylation of 3-(2-aminophenyl)-1,2,3,9-tetrahydropyrrolo[2,1-*b*]quinazolin-9-one (**8**). In the cyclization step besides (**8**) or its *N*-formylated derivative (**7**) rutaecarpine (**6**) was also obtained in 9-44 % yields<sup>6c</sup>.

Both types of alkaloids are of special interest in connection with their pharmacological activities<sup>5,6,7,8</sup>, and rutaecarpine is one of the constituent parts of the traditional ancient Chinese herbal medicines: Whu-Chu-Yu<sup>9</sup>, and Shih-Hu<sup>10</sup>.

Now we give account of a facile alternative total synthesis of rutaecarpine (**6**) and vasicolinone (**9**) by the Fischer indolization of 3-(phenylhydrazone)methyl)pyrroloquinazolinone (**4**) starting from anthranilic acid and 2-pyrrolidone.


Reaction of anthranilic acid and 2-pyrrolidone, according to Kametani's method<sup>11</sup>, in the presence of thionyl chloride<sup>12</sup> afforded deoxyvasicinone alkaloid (**1**) in 93 % yield<sup>13</sup>. The treatment of the active methylene group<sup>8d</sup> of deoxyvasicinone (**1**) by Vilsmeier-Haack reagent, phosphoryl chloride-dimethyl-

formamide, afforded 3-(dimethylamino)methylene derivative (**2**) (m.p.: 179–180°C) in 94 % yield<sup>14</sup>.

The heating of an ethanolic suspension of dimethylaminomethylene derivative (**2**) with excess of phenylhydrazine for 3h gave phenylhydrazone compound (**4**) (m.p.: 162–164°C) in 87 % yield. Besides the UV and <sup>1</sup>H NMR spectra, the signal of C(3) at 46.7 ppm and that of side-chain =CH- moiety at 136.9 ppm indicated the presence of hydrazone tautomer (**4**), instead of the hydrazine form (**3**)<sup>15</sup>.

When a solution of the hydrazone (**4**) in Dowtherm A was heated above 160°C, preferably between 180 and 190°C for 30 min, the formed rutaecarpine (**6**) gradually precipitated, and after recrystallization from DMF rutaecarpine (**6**; m.p.: 258–260°C) was obtained in 49 % yield in pure form.

In the first step the Fischer indolization of hydrazone (**4**) gave a



Scheme: i, POCl<sub>3</sub>, DMF, rt, 1h, 60 °C, 3h; ii, PhNH<sub>2</sub>, EtOH, Δ, 3h; iii, Dowtherm A, 160→190 °C, 0.5 h; iv, EtOH saturated with HCl gas, DMF, 0 °C; v, **4**·HCl, HOCH<sub>2</sub>CH<sub>2</sub>OH, 160→180 °C, 20 min.; vi, 10% aq. HCl, BuOH, 100 °C, 4h; vii, HCl-MeOH, rt; viii, 37% aq. HCHO, NaBH<sub>3</sub>CN, MeCN, rt, 2.5 h.

spiro[3H]indoleninpyrroloquinazolinone (**5**)<sup>5c</sup> besides ammonia, then in the next step **5** was rearranged into the more stable pentacyclic compound (**6**)<sup>16</sup>.

This rearrangement is very similar to that of the 3,3-disubstituted indolenines into 2,3-condensed indolo derivatives<sup>17</sup>. The mechanism of this type of ring-expansion reaction was studied by Rodriguez et al.<sup>18</sup>, and they pointed out that it is a proton catalyzed one. When the Fischer indolization of hydrazone (**4**), was carried out under acidic conditions 3-(2-amino-phenyl)tetrahydropyrroloquinazolinones (**7** or **8**) were the main products, and the formation of rutaecarpine (**6**) could be detected only by TLC. So 3-(2-formamidophenyl)pyrroloquinazolinone (**7**) (m.p.: 218-220°C) was obtained in 42 % yield from hydrazone hydrochloride<sup>19</sup> (**4.HCl**) by heating in ethylene glycol at 160°C → 180°C for 20 min.

If hydrazone (**4**) was heated in 1:5 mixture of 10 % aqueous HCl and 1-butanol at 100°C for 4h 3-(2-aminophenyl)tetrahydropyrroloquinazolinone (**8**) (m.p.: 81-83°C) was isolated in 42 % yield.

Under acidic conditions the spiroindoleninpyrroloquinazolinone (**5**), after the protonation on indolenine nitrogen, suffered a retrograde aldol reaction to give the ring-opened pyrroloquinazolinone (**7**).

The acid catalyzed rearrangement of hydrazone (**4**) is sensitive to the nature of the acid catalyst. When conc. sulfuric acid or PPA was used only tar formation occurred.

From **7**, after hydrolysis of formamido group, or from (**8**) vasicolinone (**9**) was obtained quantitatively by dimethylation of the amino group with 37% aqueous HCHO in the presence of NaBH<sub>3</sub>CN in acetonitrile at ambient temperature, according to Kaneko et al.<sup>5c</sup>

#### References and Notes

1. Nitrogen Bridgehead Compounds. Part 84. Part 83: Hermecz I.; Horváth Á. *J. Heterocycl. Chem.* in press.
2. Kőkösi J.; Hermecz I.; Szász Gy.; Mészáros Z. *Tetrahedron Lett.* 1981, 22, 4861-4862.
3. Asahina Y. *Acta Phytochim.* 1922, 1, 67.
4. Fitzgerald J. S.; Johns S. R.; Lamberton J. A.; Redcliffe A. H. Aust. *J. Chem.* 1966, 19, 151-159.
- 5a. Bergman J. *Alkaloids* 1983, 21, 29-54 and references cited therein.  
b. Bergman J.; Bergman S. *J. Org. Chem.* 1985, 50, 1246-1255.  
c. Kaneko C.; Chiba T.; Kasai K.; Miwa C. *Heterocycles* 1985, 23, 1385-1390.
6. Johnne S.; Gröger D.; Hesse M. *Helv. Chim. Acta* 1971, 54, 826-834.
- 7a. Raymond-Hamet. *Compt. Rend.* 1945, 220, 792-793.  
b. Ruyun J. *Drugs of the Future* 1985, 10, 556.

- c. Shoji N.; Umeyama A.; Takemoto T.; Kajiwara A.; Ohizumi Y. *J. Pharm. Sci.* **1986**, *75*, 612-613.
- d. Yamahara J.; Yamada T.; Kitani T.; Naitoh Y.; Fujimura H. *Chem. Pharm. Bull.* **1989**, *37*, 1820-1822.
- e. Yamahara J.; Yamada T.; Kitani T.; Naitoh Y.; Fujimura H. *J. Ethno-pharmacol.* **1989**, *27*, 185-192.
- f. Gillner M.; Bergman J.; Cambillan C.; Gustafsson J. A. *Carcinogenesis* **1989**, *10*, 651-654.
- g. Kano Y.; Zong Q.; Komatsu K. *Chem. Pharm. Bull.* **1991**, *39*, 690-692.
  
- 8a. Amin A. H.; Mehta D. R.; Samarth S. S. *Prog. Drug. Res.* **1970**, *14*, 218-268 and references cited therein.
- b. Arya V. P. *Drugs of the Future* **1981**, *6*, 373-374.
- c. John S. *Alkaloids* **1986**, *29*, 99-140 and references cited therein.
- d. Hermecz I.; Vasvári-Debreczy L. *Adv. Het. Chem.* **1986**, *39*, 281-385 and references cited therein.
  
- 9. Chu J. H. *Science Record (China)* **1951**, *4*, 279-284 [CA **1952**, *46*, 11589].
  
- 10. Ning-Taoli, Ho-I Houg, Yao Hsueh Hsueh Pao **1966**, *13*, 265-272 [CA **1966**, *65*, 3922].
  
- 11. Kametani T.; Higa T.; Loc C. V.; Ihara M.; Koizumi M.; Fukumoto K. *J. Am. Chem. Soc.* **1976**, *98*, 6186-6188.
  
- 12. Garin J.; Merino P.; Orduna J.; Tejero T.; Uriel S. *Tetrahedron Lett.* **1991**, *32*, 3263-3264.
  
- 13. Kametani T.; Loc C. V.; Higa T.; Koizumi M.; Ihara M.; Fukumoto K. *J. Am. Chem. Soc.* **1977**, *99*, 2306-2309.
  
- 14. Shakhidyatov Kh. M.; Oripov E.; Isisbaev A.; Kadyrov Ch. Sh. *Khim. Prir. Soedin.* **1976**, 825-826.
  
- 15. UV (EtOH):  $\lambda_{\text{max}}$  368 (log $\epsilon$  4.65); 315 (3.92); 284 (4.02); 276 (4.07); 224nm (4.30). IR (KBr):  $\nu_{\text{max}}$  3400; 3300-2600; 1660  $\text{cm}^{-1}$  (C=O);  $^1\text{H-NMR}$  (80MHz CDCl<sub>3</sub>, TMS, ppm)  $\delta$  2.44 (*m*, 2H, 2-CH<sub>2</sub>), 3.8-4.4 (*m*, 2H, 1-CH<sub>2</sub>), 4.05 (*m*, 1H, 3-H), 7.64 (*d*,  $J_{3,3}$ =6.8 Hz, 1H, 3'-CH), 6.5-7.9 (*m*, 8H, Ph+5-, 6- and 7-H), 8.25 (*d*,  $J$ =8 Hz, 1H, 8-H), 10.05 (*s*, 1H, NH).  $^{13}\text{C-NMR}$  (20.1MHz, CDCl<sub>3</sub>, TMS, ppm),  $\delta$  45.0 (*t*, C-1), 24.4 (*t*, C-2); 46.7 (*d*, C-3), 149.8 (*s*, C-3a), 149.2 (*s*, C-4a), 125.9 (*d*, C-5), 134.3 (*d*, C-6 and C-7), 127.3 (*d*, C-8), 120.6 (*s*, C-8a), 160.1 (*s*, C-9), 136.9 (*d*, C-3'), 119.9, 129.2, 118.2, and 145.8 (carbons of Ph).
  
- 16. Semiempirical quantum chemical calculation by AM1 method indicated that the heat of formation of rutaecarpine (**6**) (322.58 KJ/mol) is about 70KJ/mol less than that of the most stable conformation of spiro compound (**5**) (391.18 KJ/mol).
  
- 17a. Wenkert E.; Dave K. G.; Gnewuch C. T.; Sprague P. W. *J. Am. Chem. Soc.* **1968**, *90*, 5251-5256.
- b. Jackson A. H.; Naidoo B.; Smith P. *Tetrahedron* **1968**, *24*, 6119-6129.
  
- 18. Rodriguez J. G.; Benito Y.; Temprano F. *J. Heterocycl. Chem.* **1985**, *22*, 1207-1210.
  
- 19. To solution of hydrazone (**4**) in DMF saturated ethanolic hydrogen chloride was added at 0°C. The precipitated hydrochloride salt of hydrazone (**4**) was filtered off. Yield 78 %, m.p.:> 217°C (decomp).